We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The UK’s drug pricing watchdog has recommended reimbursement of Novartis’ innovative drug Cosentyx for ankylosing spondylitis, but only if it provides it at a discount.